WHO: The World Health Organization said last day that it has pre-qualified the arthritis treatment tocilizumab for use in hospitalized patients with Kovid-19. The monoclonal antibody created by Swiss pharma giant Roche helps reduce the risk of death and less hospitalization in people with COVID-19. The WHO has already recommended its use for the treatment of severe COVID patients in hospitals, like the European Union, including the United States.
According to the information, it is available in less quantity and is quite expensive. A single dose goes up to $600 in low-income countries. The WHO said that its prior qualification could help make it more available. Tocilizumab was previously used for the treatment of arthritis in most of 120 countries. At the same time, during epidemics, it has been shown to be helpful in suppressing a dangerous cytokine storm.
Price was discussed
WHO discussed Tocilizumab with Rosh and discussed how to reduce its prices and reach low-income countries. At the same time, AFP now insisted that the prequalification was for Roche products. Several generic companies are already producing tocilizumab and many of them applied for prequalification. At the same time, if they follow the WHO standard, then they will be able to enter the international markets.
Read also.
Be the first to read breaking news in Hindi aajsamacharindia.com| Today’s latest news, live news updates, read most reliable Hindi news website aajsamacharindia.com|
Like us on Facebook or follow us on Twitter for breaking news and live news updates.
